Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics Limited announced the completion of dosing in its Phase 1 Single Ascending Dose study for its drug candidate PYC-001, aimed at treating Autosomal Dominant Optic Atrophy (ADOA), a blinding eye disease with no current approved treatments. The company will present promising safety and early efficacy data at the Neuro-Ophthalmology Society of Australia conference, indicating no serious adverse events and an early trend of improvement in visual acuity. PYC plans to advance PYC-001 into a global Phase 1/2 Multiple Ascending Dose study in Q4 2025, aiming to establish clinical proof-of-concept before progressing to a registrational trial.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing RNA therapies to treat genetic diseases. The company leverages its proprietary drug delivery platform to enhance the effectiveness of precision medicines, particularly targeting monogenic diseases, which have a higher likelihood of success in clinical development.
Average Trading Volume: 670,452
Technical Sentiment Signal: Buy
Current Market Cap: A$743.7M
For detailed information about PYC stock, go to TipRanks’ Stock Analysis page.